These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 26429859)

  • 1. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
    Canella A; Cordero Nieves H; Sborov DW; Cascione L; Radomska HS; Smith E; Stiff A; Consiglio J; Caserta E; Rizzotto L; Zanesi N; Stefano V; Kaur B; Mo X; Byrd JC; Efebera YA; Hofmeister CC; Pichiorri F
    Oncotarget; 2015 Oct; 6(31):31134-50. PubMed ID: 26429859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
    Bjorklund CC; Baladandayuthapani V; Lin HY; Jones RJ; Kuiatse I; Wang H; Yang J; Shah JJ; Thomas SK; Wang M; Weber DM; Orlowski RZ
    Leukemia; 2014 Feb; 28(2):373-83. PubMed ID: 23760401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
    Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
    Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1-C is a target in lenalidomide resistant multiple myeloma.
    Yin L; Tagde A; Gali R; Tai YT; Hideshima T; Anderson K; Avigan D; Kufe D
    Br J Haematol; 2017 Sep; 178(6):914-926. PubMed ID: 28643330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
    Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
    Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
    Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
    Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
    Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
    Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
    Chauhan D; Singh AV; Ciccarelli B; Richardson PG; Palladino MA; Anderson KC
    Blood; 2010 Jan; 115(4):834-45. PubMed ID: 19965674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
    Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
    Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.
    Maïga S; Gomez-Bougie P; Bonnaud S; Gratas C; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
    Br J Cancer; 2013 May; 108(9):1801-6. PubMed ID: 23632478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
    Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
    Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
    Won HR; Lee DH; Yeon SK; Ryu HW; Kim GW; Kwon SH
    Int J Oncol; 2019 Aug; 55(2):499-512. PubMed ID: 31268156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
    De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
    Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
    Ocio EM; Fernández-Lázaro D; San-Segundo L; López-Corral L; Corchete LA; Gutiérrez NC; Garayoa M; Paíno T; García-Gómez A; Delgado M; Montero JC; Díaz-Rodríguez E; Mateos MV; Pandiella A; Couto S; Wang M; Bjorklund CC; San-Miguel JF
    Leukemia; 2015 Mar; 29(3):705-14. PubMed ID: 25102946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
    Hirano M; Imai Y; Kaito Y; Murayama T; Sato K; Ishida T; Yamamoto J; Ito T; Futami M; Ri M; Yasui H; Denda T; Tanaka Y; Ota Y; Nojima M; Kamikubo Y; Gotoh N; Iida S; Handa H; Tojo A
    J Exp Clin Cancer Res; 2021 Mar; 40(1):110. PubMed ID: 33757580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
    Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
    Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
    Kim GW; Yoo J; Won HR; Yeon SK; Lee SW; Lee DH; Jeon YH; Kwon SH
    Leuk Res; 2020 Aug; 95():106398. PubMed ID: 32512378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.
    Zhang L; Bi E; Hong S; Qian J; Zheng C; Wang M; Yi Q
    Oncotarget; 2015 Nov; 6(34):36032-40. PubMed ID: 26447613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.